Phathom Pharmaceuticals (PHAT) Return on Sales (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Return on Sales data on file, last reported at 0.01% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.01%, up 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 3.0% YoY), and the FY2025 annual result was 0.01%, up 5.0% from the prior year.
• Return on Sales slipped to 0.01% in Q1 2026 per PHAT's latest filing, from 0.0% in the prior quarter.
• Over five years, Return on Sales peaked at 0.0% in Q4 2025 and troughed at 1.17% in Q4 2023.
• A 4-year average of 0.19% and a median of 0.03% in 2024 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2024 and 2025: Return on Sales surged 114 bps in 2024, then rose 2 bps in 2025.
• A 4-year view of Return on Sales shows it stood at 1.17% in 2023, then jumped by 98 bps to 0.03% in 2024, then surged by 85 bps to 0.0% in 2025, then sank by 38 bps to 0.01% in 2026.
• Business Quant data shows PHAT's Return on Sales at 0.01% in Q1 2026, 0.0% in Q4 2025, and 0.01% in Q3 2025.